E
EMISPHERE TECHNOLOGIES
Innovative drug delivery solutions enhancing oral bioavailability of peptides, proteins, and large molecules
About EMISPHERE TECHNOLOGIES
Emisphere Technologies specializes in advanced drug delivery systems, focusing on enhancing the oral bioavailability of peptides, proteins, and large molecules. The company operates in the pharmaceutical and biotechnology sectors, partnering with other firms to license its proprietary drug delivery technology, including Eligen B12. Emisphere's core business model revolves around research and development, leveraging its extensive library of carriers to facilitate the absorption of drugs without altering their chemical form or biological integrity. This technology is particularly useful for drugs that are typically degraded by the digestive tract, such as protein and peptide drugs. By inhibiting acid and enzyme-mediated degradation, Emisphere's solutions allow these drugs to be absorbed effectively via the gastrointestinal epithelium. The company generates revenue through partnerships and licensing agreements, providing its technology to pharmaceutical companies looking to convert injectable therapeutics into oral formulations.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Dec 2025 | $15M | — | MHR Fund Management | ↗ |
| ACQUISITION✓Exit | Nov 2020 | $1.4B | $1.4B | Novo Nordisk | — |
Growth signals
Latest recorded traffic for EMISPHERE TECHNOLOGIES is 340 monthly website visits, up 13.3% over the last three months. EMISPHERE TECHNOLOGIES's team declined 13.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 LongevitycourseA free 18-hour crash course to transition your career into longevity |
— | Operational | — | — | — |
 AyomicsDiagnostics and biomarkers for monitoring aging and age-related health risks |
Zug, Switzerland | Closed | |||
 Alba HealthDeveloper of a gut microbiome test developed specifically for children, in order to fight chronic diseases |
Stockholms kommun, Sweden | Operational | |||
 BrightmindAI-powered, at-home neuromodulation device for migraine therapy |
Vienna, Austria | Operational | |||
 AnibiomeLongevity biotech startup |
Zagreb, Croatia | Operational | |||
 mama healthBuilding the AI-native Bloomberg Terminal for Pharma Commercial Teams |
Berlin, Germany | Operational | |||
 ElevateMeAt-home blood tests with personalized AI-driven health insights |
London, United Kingdom | Operational | |||
 NeedleSafeThe technology is able to generate transient antiseptic environment preventing the infections caused by multi-drug resistant bacteria |
Spain | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
MHR Fund Management
Other known investors1 additional known investor
Novo Nordisk
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about EMISPHERE TECHNOLOGIES on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EMISPHERE TECHNOLOGIES’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.